Cargando…
Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R)
AIMS: The ABSORB bioresorbable vascular scaffold raised safety concerns due to higher rates of scaffold thrombosis (ScT) and adequate scaffold diameter and length for scaffold technology. Smaller scaffold diameter (SScD, 2.5 mm) was an infrequently quoted predictor of major adverse cardiac events (M...
Autores principales: | Zaczkiewicz, Myron, Wein, Bastian, Graf, Matthias, Zimmermann, Oliver, Kastner, Johannes, Wöhrle, Jochen, Thomas, Riemer, Hamm, Christian, Torzewski, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096743/ https://www.ncbi.nlm.nih.gov/pubmed/32258361 http://dx.doi.org/10.1016/j.ijcha.2020.100501 |
Ejemplares similares
-
Quality of life of patients with coronary heart disease treated with the bioresorbable vascular scaffold (ABSORB™): 2-year results from the GABI-R-registry
por: Pahmeier, Kathrin, et al.
Publicado: (2022) -
Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry
por: Gori, Tommaso, et al.
Publicado: (2019) -
Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan
por: Gogas, Bill D., et al.
Publicado: (2015) -
Gaby Brimmer
por: Brimmer, Gabriela, 1947-
Publicado: (1979) -
“The Unpredictable ABSORB” – Very Late Stent Thrombosis of Bioresorbable Vascular Scaffold
por: Pradhan, Akshyaya, et al.
Publicado: (2019)